Pfizer, Amgen Reportedly Bidding For Russia’s Biocad
This article was originally published in PharmAsia News
Executive Summary
Bidding could top $1 billion for the Russian biosimilars play, which is developing copies of key Roche drugs like Herceptin, Rituxan and Avastin, according to Bloomberg.